

## DAFTAR PUSTAKA

- Alon, T. *et al.* 2020. ‘The Impact of COVID-19 on Gender Equality’, *National Bureau Of Economic Research*. doi: 10.1007/s10272-021-0992-7.
- Andrews, N. *et al.* 2022. ‘Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant’, *New England Journal of Medicine*, 386(16), pp. 1532–1546. doi: 10.1056/nejmoa2119451.
- Araf, Y. *et al.* 2022. ‘Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines’, *Journal of Medical Virology*, (January). doi: 10.1002/jmv.27588.
- Ariyanti, F. *et al.* 2021. ‘How Risky People of Getting COVID-19 based on their Daily Activities?’, *Kesmas: National Public Health Journal*, 16(4), pp. 298–306. doi: 10.21109/kesmas.v16i4.5005.
- BPS DKI Jakarta. 2020. Master Wilayah Provinsi DKI Jakarta 2020. Available at: <https://jakarta.bps.go.id/publication/2020/12/23/b6e087ddc2d8b95e694090e7/statistik-hortikultura-provinsi-dki-jakarta-2019.html>.
- Centers for Disease Control and Prevention. 2016. ‘The Whole Genome Sequencing (WGS ) Process’.
- Centers for Disease Control and Prevention. 2021. ‘COVID-19 Vaccines are Effective’. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/index.html>.
- Centers for Disease Control and Prevention. 2022. What You Need to Know About Variants. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/variants/about-variants.html> (Accessed: 3 March 2022).
- Chaturvedi, D. and Chakravarty, U. 2021. ‘Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A’, *Infection, Genetics and Evolution*, 92(February), p. 104834. doi: 10.1016/j.meegid.2021.104834.
- Damayanti, R. *et al.* 2022. ‘Faktor-Faktor yang Berhubungan dengan Kejadian Coronavirus Disease 2019 (COVID-19) di Provinsi Jawa Tengah’, 7(1), pp. 431–443.
- Dinas Kesehatan DKI Jakarta. 2022. Cakupan Vaksinasi Fasilitas Kesehatan di Kecamatan. Available at: <https://corona.jakarta.go.id/cakupan-vaksinasi> (Accessed: 19 June 2022).
- Eggink, D. *et al.* 2022. ‘Increased risk of infection with SARS-CoV-2 Omicron

- BA.1 compared with Delta in vaccinated and previously infected individuals, the Netherlands, 22 November 2021 to 19 January 2022', *Eurosurveillance*, 27(4). doi: 10.2807/1560-7917.ES.2022.27.4.2101196.
- Elsland, S. L. van. 2021. Omicron largely evades immunity from past infection or two vaccine doses, Imperial College London. Available at: <https://www.imperial.ac.uk/news/232698/modelling-suggests-rapid-spread-omicron-england/>.
- Galván-Tejada, C. E. et al. 2020. 'Persistence of covid-19 symptoms after recovery in mexican population', *International Journal of Environmental Research and Public Health*, 17(24), pp. 1–12. doi: 10.3390/ijerph17249367.
- Gausman, J. and Langer, A. 2020. 'Sex and Gender Disparities in the COVID-19 Pandemic', *Journal of Women's Health*, 29(4), pp. 465–466. doi: 10.1089/jwh.2020.8472.
- Gautret, P. et al. 2022. 'The severity of the first 207 infections with the SARS-CoV-2 Omicron BA.2 variant, in Marseille, France, December 2021–February 2022', *Journal of Medical Virology*, (February), pp. 3494–3497. doi: 10.1002/jmv.27760.
- Gazit, S., Shlezinger, R. and Perez, G. 2021. 'Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections', *The Preprint Server for Health Sciences*, 62(1), p. 1. doi: 10.1016/j.fueleneab.2020.12.001.
- Gebhard, C. et al. 2020. 'Impact of sex and gender on COVID-19 outcomes in Europe', *Biology of Sex Differences*, 11(29), pp. 1–13. doi: 10.1186/s13293-020-00301-y.
- Goldberg, Y. et al. 2022. 'Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2', *New England Journal of Medicine*, 386(23), pp. 2201–2212. doi: 10.1056/nejmoa2118946.
- He, X. et al. 2021. 'SARS-CoV-2 Omicron variant: Characteristics and prevention', *MedComm*, 2(4), pp. 838–845. doi: 10.1002/mco2.110.
- Hidayani, W. R. 2020. 'Faktor Faktor Risiko Yang Berhubungan Dengan COVID-19 : Literature Review', *Jurnal Untuk Masyarakat Sehat (JUKMAS)*, 4(2), pp. 120–134. doi: 10.52643/jukmas.v4i2.1015.
- Hidayat, A. A. 2015. Metode Penelitian Kesehatan Paradigma Kuantitatif. 1st edn. Edited by Aulia. Surabaya: Health Books Publishing.
- Kadir, A., Deby, S. and Muhammad, A. 2022. 'A Systematic Review of Omicron Outbreak in Indonesia : A Case Record and Howthe Country is Weathering the New Variant of COVID-19', *European Journal of Molecular & Clinical*

- Medicine*, 09(01), pp. 364–373.
- Kemenkes RI. 2014. ‘Info Datin Kemenkes: Situasi dan Analisis Diabetes’, *Pusat Data dan Informasi Kementerian Kesehatan RI*, p. 7. doi: 24427659.
- Kemenkes RI. 2014. ‘Infodatin: Situasi Kesehatan Jantung’, *Pusat Data dan Informasi*, p. 8.
- Kemenkes RI. 2014. ‘Pusdatin: Hipertensi’, *Infodatin*, pp. 1–7. doi: 10.1177/109019817400200403.
- Kemenkes RI. 2021. ‘Buku Saku: Tanya Jawab Seputar Vaksinasi COVID-19’, in, pp. 1–40.
- Kemenkes RI. 2021. ‘Surat Edaran Nomor HK.02.01/MENKES/1391/2021 tentang Pencegahan dan Pengendalian Kasus COVID-19 Varian Omicron (B.1.1.529)’.
- Kemenkes RI. 2022. Kasus Konfirmasi Terus Meningkat, Kemenkes Terbitkan Surat Edaran Pencegahan dan Pengendalian COVID-19 Varian Omicron. Available at: <https://sehatnegeriku.kemkes.go.id/baca/umum/20220104/3839091/kasus-konfirmasi-terus-meningkat-kemenkes-terbitkan-surat-edaran-pencegahan-dan-pengendalian-covid-19-varian-omicron/> (Accessed: 11 March 2022).
- Kemenkes RI. 2022. Positivity Rate Kasus Omicron Melandai. Available at: <https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20220222/0339374/positivity-rate-kasus-omicron-melandai/> (Accessed: 1 March 2022).
- Kemenkes RI. 2022. Puncak Gelombang Kenaikan Kasus Omicron Diprediksi Pertengahan Februari, Kemenkes Kebut Vaksinasi Booster di Wilayah Jabodetabek. Available at: <https://sehatnegeriku.kemkes.go.id/baca/umum/20220116/4739162/puncak-gelombang-kenaikan-kasus-omicron-diprediksi-pertengahan-februari-kemenkes-kebut-vaksinasi-booster-di-wilayah-jabodetabek/> (Accessed: 1 March 2022).
- Kemenkes RI. 2022. Surat Edaran Nomor HK.02.01/MENKES/18/2022 tentang Pencegahan dan Pengendalian Kasus COVID-19 Varian Omicron (B.1.1.529), Surat Edaran Menteri Kesehatan.
- Kertapati, D. 2021. Omicron Pertama Masuk Indonesia, *Mediakom Kemenkes RI*. Available at: <https://mediakom.kemkes.go.id/v2/2022/01/omicron-pertama-masuk-indonesia/> (Accessed: 11 March 2022).
- Li, B. et al. 2020. ‘Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China’, *Clinical Research in Cardiology*, 109(5), pp. 531–538.

- doi: 10.1007/s00392-020-01626-9.
- Li, X. *et al.* 2021. ‘Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis’, *PLoS ONE*, 16(5 May), pp. 1–21. doi: 10.1371/journal.pone.0250602.
- Mallapaty, S. 2022. ‘Most US kids have caught the coronavirus, antibody survey finds’, *Nature*, 605(7909), p. 207. doi: 10.1038/d41586-022-01231-y.
- Marfe, G., Perna, S. and Shukla, A. 2021. ‘Effectiveness of COVID-19 vaccines and their challenges (Review)’, *Experimental and Therapeutic Medicine*, 22(6), pp. 1–19. doi: 10.3892/etm.2021.10843.
- Nisa, N. 2019. Faktor-Faktor yang Berhubungan dengan Pemilihan Tenaga Penolong Persalinan di Desa Banjarwaringin Kecamatan Salopa Kabupaten Tasikmalaya Tahun 2019, *Tesis Program Sarjana*. Universitas Siliwangi.
- Nurfalah, W. O. *et al.* 2021. ‘Faktor Risiko Kejadian COVID-19 Pada Pasien Di RSUD Sayang Rakyat Kota Makassar’, *Window of Public Health Journal*, 2(4), pp. 1487–1497. doi: 10.33096/woph.v2i4.733.
- Rashedi, J. *et al.* 2020. ‘Risk Factors for COVID-19’, (December).
- Rosado, L. S. 2022. Covid-19 Update Omicron Variant: What We Know, Behavioral & Community Health. Available at: <https://www.dutchessny.gov/Departments/DBCH/docs/Omicron-What-We-Know-Quarantine-Instructions.pdf>.
- Rosiello, D. F., Anwar, S. and Yufika, A. 2021. ‘Acceptance of COVID-19 vaccination at different hypothetical efficacy and safety levels in ten countries in Asia, Africa, and South America’, *Narra Journal*, 1(3), pp. 1–16.
- Sains, J. K. *et al.* 2021. ‘Faktor Risiko Kejadian Covid-19 di RSUD Undata Palu’, *Jurnal Kolaboratif Sains*, 04, pp. 648–657.
- Skarbinski, J. *et al.* 2022. ‘Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study’, *The Lancet Regional Health - Americas*, 12, p. 100297. doi: 10.1016/j.lana.2022.100297.
- Sonyorini, S. H. and Sulastri, S. 2021. ‘Hubungan Karakteristik Masyarakat Dengan Kejadian COVID-19 Di Desa Payung Kecamatan Weleri’, *Jurnal Surya Muda*, pp. 1–16. doi: 10.38102/jsm.v0i0.135.
- Styawan, A. 2020. ‘Pandemi Covid-19 Dalam Perspektif Demografi’, in, pp. 182–189.

- Susanti, K. N. and Azam, M. 2016. ‘Hubungan Status Vaksinasi Bcg, Riwayat Kontak Dan Personal Hygiene Dengan Kusta Di Kota Pekalongan’, *Unnes Journal of Public Health*, 5(2), p. 130. doi: 10.15294/ujph.v5i2.10121.
- Tang, J. et al. 2022. ‘Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C’, *Nature Communications*, 13(1), pp. 1–10. doi: 10.1038/s41467-022-30649-1.
- UNICEF. 2022. What We Know about The Omicron Variant. Available at: <https://www.unicef.org/coronavirus/what-we-know-about-omicron-variant> (Accessed: 1 March 2022).
- World Health Organization. 2021. Coronavirus disease (COVID-19). Available at: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19> (Accessed: 3 March 2022).
- World Health Organization. 2021. ‘Memperkuat Kesiapsiagaan menghadapi Omicron (B.1.1.529): Penjelasan Teknis dan Aksi Prioritas untuk Negara-Negara Anggota’, p. 9.
- Yonekawa, A. and Shimono, N. 2022. ‘Clinical Significance of COVID-19 and Diabetes: In the Pandemic Situation of SARS-CoV-2 Variants Including Omicron (B.1.1.529)’, *Biology*, 11(3), pp. 1–18. doi: 10.3390/biology11030400.
- Zhang, L. and Liu, Y. 2020. ‘Potential interventions for novel coronavirus in China: A systematic review’, *Journal of Medical Virology*, 92(5), pp. 479–490. doi: 10.1002/jmv.25707.